Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 2Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Neurofibromatosis 1 6Neoplasm Metastasis 6Solid Tumours 5Neoplasms 5Melanoma 5Neurofibroma, Plexiform 4Lung Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 2Biliary Tract Neoplasms 2Uveal Melanoma 1Solid Tumors 1Renal Insufficiency 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Muscle Invasive Bladder Cancer 1Locally Advanced or Metastatic Solid Tumors 1Kidney Neoplasms 1Healthy Volunteers Pharmacokinetic Study 1Disease Progression 1Differentiated Thyroid Cancer 1Colonic Neoplasms 1Advanced Non Small Cell Lung Cancer 1Advanced Cancer 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × AZD 6244 × Clear all
NCT00463814 2026-05-29

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

AstraZeneca

Phase 1 Active not recruiting
58 enrolled
Tumor-Agnostic

Neoplasms

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01605916 2016-10-21

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

AstraZeneca

Phase 1 Completed
33 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02322749 2016-08-31

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

AstraZeneca

Phase 1 Completed
48 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT02238782 2016-04-05

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

AstraZeneca

Phase 1 Completed
21 enrolled 4 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡